

Express Mail Label No. EL304655126US  
DATE OF DEPOSIT: September 15, 2000

Attorney's Ref. No. 1115-005/ddh

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box PATENT APPLICATION  
ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Transmitted herewith for filing is the patent application of:  
Inventor: Michael A. Kuzyk et al.

For: VACCINES AND AGENTS FOR INDUCING IMMUNITY IN FISH AGAINST RICKETTSIAL  
DISEASES, AND ASSOCIATED PREVENTATIVE THERAPY

Enclosed are:

- [X] Patent application with 21 pages of specification, 3 pages of claims, an abstract, and 11 sheets of drawings.  
[X] Combined Declaration and Power of Attorney (unsigned)  
[X] **This is a non-provisional application claiming priority from prior application no 60/154,437**

CLAIMS AS FILED					
For	Number Filed		Number Extra	Rate	Basic Fee
Total claims	32	-20	12	=	0
Independent Claims	13	-3	10	=	0
TOTAL FILING FEE					

Respectfully submitted,



Douglas D. Hancock  
Registration No. 35,889

ipsolon llp  
4370 NE Halsey Street  
Portland, Oregon 97213  
Telephone: (503) 249-7066  
cc: Robert Barrigar

## **Vaccines and Agents for Inducing Immunity in Fish Against Rickettsial Diseases, And Associated Preventative Therapy**

### **Reference to Related Applications**

This application claims the benefit of U.S. Provisional Application No. 60/154,437, filed September 17, 1999.

### **Field of the Invention**

This invention relates generally to the field of obligate intracellular bacteria, and in particular to agents of rickettsia type diseases, specifically *Piscirickettsia salmonis* in aquatic poikilotherms. The invention also encompasses isolated genes encoding outer surface antigens of *P. salmonis* and the diagnostic and therapeutic use (including in particular the preparation of a recombinant vaccine to prevent or reduce the incidence of infection by *P. salmonis* and other rickettsial diseases) of such antigens or their homologues.

In particular aspects, this invention relates to the use of the 17 kDa outer surface lipoprotein (OspA) of *Piscirickettsia salmonis*, or its homologues, as the basis of, or part thereof, a recombinant vaccine for salmonid rickettsial septicaemia and other rickettsial diseases. This invention also relates to the augmentation of protective immunity by the inclusion of promiscuous T lymphocyte epitopes (TCE's) in fusion protein constructs in salmonids. This invention also relates to the use of bacterial protein inclusion bodies as a source of the protective immunogen.

### **Background of the Invention**

The order *Rickettsiales* historically encompassed any intracellular bacterium and taxonomy was based on only a few phenotypic characteristics (Drancourt and Raoult, 1994). More recently, 16S rRNA sequence similarity studies have helped to better define the taxonomy of the order *Rickettsiales* (Drancourt and Raoult, 1994). Rickettsiae cause a variety of medically significant diseases in humans including typhus fever, Rocky Mountain spotted fever, and boutonneuse fever (Pang and Winkler, 1994; Vishwanath, *et al.*, 1990). Rickettsiae are also agriculturally significant, and are the aetiological agents of a variety of veterinary diseases (Rikihisa, 1991).

The past decade has been a renaissance in the identification of rickettsial and rickettsial-like infections as the aetiological agents of poorly understood diseases and as emerging pathogens (Anderson, 1997; Azad, *et al.*, 1997; Davis, *et al.*, 1998; Fryer and Mael, 1997; Stenos, *et al.*, 1998). Inherent difficulties are associated with rickettsials: it is very difficult to grow large quantities of rickettsiae; rickettsiae have very slow growth rates; and rickettsiae are difficult to separate from host cell material (Higgins, *et al.*, 1998). Although rickettsiae lack a characterized genetic system for genetic manipulation (Mallavia, 1991), the advent of recombinant DNA technology has revolutionized rickettsial research. Characterization of rickettsial pathogenesis and functional analysis of rickettsial antigens has largely relied upon antibody inactivation studies (Li and Walker,

1998; Messick and Rikihisa, 1994; Seong, *et al.*, 1997). Recently major rickettsial antigens have been identified and characterized further upon sub-cloning into *Escherichia coli* (Anderson, *et al.*, 1990; Anderson, *et al.*, 1987; Carl, *et al.*, 1990; Ching, *et al.*, 1992; Ching, *et al.*, 1996; Hahn and Chang, 1996; Musoke, *et al.*, 1996). Successful transformation of *Rickettsia typhi* (Troyer, *et al.*, 1999) and *Rickettsia prowazekii* (Rachek, *et al.*, 1998) have recently raised exciting prospects for the future of rickettsia research.

Antibody studies of rickettsiae have shown that inactivation of specific rickettsial surface proteins can inhibit entry into host cells and establishment of infection (Anacker, *et al.*, 1985; Li and Walker, 1998; Messick and Rikihisa, 1994). Failed attempts at constructing vaccines against human rickettsial diseases have been based on preparations of inactivated whole cells (Sumner, *et al.*, 1995). Although these whole cell vaccines elicit protective responses in animal models, they are only partially effective when used in humans (Sumner, *et al.*, 1995). Current vaccine strategies using recombinantly expressed rickettsial proteins identified by antibody studies have been shown to successfully elicit protective immune responses against bacterial challenge (McDonald, *et al.*, 1987; Sumner, *et al.*, 1995).

*Piscirickettsia salmonis* is the first rickettsiae to be isolated from an aquatic poikilotherm (Fryer, *et al.*, 1990). *P. salmonis* is the aetiological agent of salmonid rickettsial septicaemia (SRS), and is an economically significant pathogen of salmonids that is responsible for extensive mortalities in the cold water aquaculture industry. *P. salmonis*, a gram-negative obligate intracellular bacterium, was first observed in 1989 in a diseased, moribund coho salmon from a saltwater net pen site on the coast of Chile (Bravo and Campos, 1989). It is now known that *P. salmonis* is geographically more widespread than was initially suspected, and has recently been observed in Ireland (Rodger and Drinan, 1993), Scotland, Norway, and on the Pacific coast of Canada (Brocklebank, *et al.*, 1993).

*P. salmonis* has been observed to infect a wide range of salmonid species and causes a systemic infection that targets the kidney, liver, spleen, heart, brain, intestine, ovary, and gills of salmonids (Cvitanich, *et al.*, 1991). Pleomorphic, predominantly coccoid bacteria that range in diameter from 0.5 to 1.5 µm are found within cytoplasmic vacuoles of cells from infected tissues (Bravo and Campos, 1989). While initially difficult to culture, *P. salmonis* was successfully isolated from the kidney of a diseased adult coho salmon on an immortal chinook salmon embryo cell line (Fryer, *et al.*, 1990). Fryer *et al.* (Fryer, *et al.*, 1992) conducted a 16S rRNA sequence similarity study which placed *P. salmonis* in its own genus and species within the order Rickettsiales. *P. salmonis* is most closely related to *Coxiella burnetii* and *Wolbachia persica* with 87.5% and 86.3% sequence similarity respectively (Fryer, *et al.*, 1992). *P. salmonis* appears to belong within the tribe Ehrlichieae because of its morphological characteristics (Fryer, *et al.*, 1992).

Efficacy of antibiotic treatment of SRS is poor because of the intracellular nature of *P. salmonis*, thereby making management of the disease difficult (Lannan and Fryer, 1993). To effectively prevent and control SRS, vaccine development is desirable. However, vaccines prepared from whole cell bacterins of mammalian rickettsiae have shown disappointing protection in trials (Hickman, *et al.*, 1991).

Incorporation of highly immunogenic T lymphocyte epitopes (TCE's) into chimeric fusion proteins is an elegant extension of the principles that underlie the immunostimulatory effect of toxoid carrier proteins on conjugated haptens (Bixler and Pillai, 1989). Toxoids provide TCE's that are required to elicit a strong T helper cell-mediated immune response against haptens (Bixler and Pillai, 1989). Incorporation of TCE's into synthetic peptide or chimeric fusion proteins can have an immunostimulatory effect on other T cell and humoral epitopes within the peptide or protein (Hathaway, *et al.*, 1995; Kjerrulf, *et al.*, 1997; O'Hern, *et al.*, 1997; Pillai, *et al.*, 1995; Valmori, *et al.*, 1992). To minimize genetic restriction of these immunostimulatory responses, promiscuous TCE's capable of binding major histocompatibility complex (MHC) molecules from a variety of haplotypes are used in chimeric vaccine constructs. Tandem repeats of TCE's can also often improve immunogenicity of chimeric proteins better than single TCE's (Kjerrulf, *et al.*, 1997; Partidos, *et al.*, 1992).

The *Clostridium tetani* tetanus toxin P2 (tt P2) and measles virus fusion protein (MVF) epitopes have been established as strong TCE's that exhibit promiscuous binding to various MHC haplotypes and are highly immunogenic in human and murine models (Demotz, *et al.*, 1989; Panina-Bordignon, *et al.*, 1989; Partidos and Steward, 1990). Both tt P2 and MVF TCE's are MHC class II restricted and are able to bind MHC class II molecules from a wide variety of haplotypes. Genetic restriction of murine responses to malarial epitopes has been overcome by incorporation of the tt P2 epitope into synthetic peptide-based malarial vaccines (Valmori, *et al.*, 1992).

### Summary of the Invention

The present inventors have characterized the surface antigens of the bacterial pathogen *P. salmonis* and identified and characterized an immunoreactive antigen, namely the 17 kDa outer surface lipoprotein OspA of *P. salmonis*, as well as the nucleic acid segment that encodes the OspA immunoreactive antigen. This discovery enables the development of diagnostic techniques (including the use of hybridization probes and primers) as well as the production of specific antigens and antibodies that may be used in immunization techniques for inducing immunity against *P. salmonis* and other rickettsial diseases. In particular, the discovery enables the development of recombinant vaccines for SRS and other rickettsial diseases based on the 17 kDa lipoprotein OspA. In one embodiment, the invention comprises an isolated nucleic acid segment (SEQ ID NO:1) encoding a 17 kDa immunodominant protein of *P. salmonis*, which is immunoreactive with anti-*P. salmonis* serum. In another embodiment, the invention comprises a nucleic acid segment that encodes a protein having the amino acid sequence of SEQ ID NO:2, including variants that retain immunogenicity. Due to the degeneracy of the genetic code and the possible presence of flanking nucleic acid fragments outside of the coding region, it will be understood that many different nucleic acid sequences may encode the amino acid sequence of SEQ ID NO:2 and variants, and that all such sequences would be encompassed within the present invention.

The nucleic acid segment of the invention may be modified for optimal codon usage and expression in a host cell line (*i.e.* "optimized") as shown, for example, in SEQ ID NO:3, and may be operably

linked to a recombinant promoter and a TCE fusion partner as, for example, in SEQ ID NO:5.

In a further embodiment, the invention relates to the use of OspA as an immunogen and to the use of OspA in a recombinant vaccine to reduce the incidence of infection by *P. salmonis* and other rickettsial diseases.

The slow growing, rickettsia-like, piscine pathogen, *P. salmonis*, was grown *en mass* on chinook salmon (*Oncorhynchus tshawytscha*) embryo cell line monolayers (CHSE-214) to purify enough *P. salmonis* to allow genomic deoxyribonucleic acid (DNA) isolation. A genomic expression library was constructed and screened with high titre anti-*P. salmonis* rabbit serum identifying immunoreactive clones that encoded a common region of *P. salmonis* DNA. A 4,983 bp insert was excised in *E. coli* and *Exo III/S1* deletion clones were sequenced. The insert contained 4 intact open reading frames (ORF) one of which encoded a homologue, *ospA*, of a genus-specific, rickettsia-like, outer membrane 17 kDa lipoprotein antigen. OspA was recognized by both convalescent coho salmon (*Oncorhynchus kisutch*) serum and rabbit antiserum to both 10 & 20 residue peptides based on predicted protein sequence. The codon usage of the *ospA* ORF was optimized for expression in *E. coli* by construction of a synthetic version of the *ospA* gene. An N-terminal fusion partner was cloned in frame with the *ospA* gene as well as tt P2 and MVF TCE's all under the control of both T7 and lambda phage promoters to direct expression into inclusion bodies as well as to facilitate large scale expression of the protein. The various OspA fusion proteins were purified from *E. coli* as the insoluble inclusion body fraction of a whole cell lysate. Suspensions of the insoluble fraction were formulated with an adjuvant and used as a vaccine to immunize coho salmon. Vaccinates showed both an increase in anti-OspA antibody production and increased *in vitro* stimulation of whole lymphocyte populations by OspA fusion protein. Eight weeks post-vaccination, the salmon were challenged with virulent suspensions of *P. salmonis*. The results indicated that the vaccine was protective against virulent challenge and that immunogenicity and protection were augmented by the incorporation of promiscuous TCE's into the OspA fusion protein.

Functional presentation of antigen by salmonid MHC class I and II complexes analogous to the role of MHC class I and II of mammals and birds has not been confirmed in teleosts. As a result, algorithms do not exist for predicting peptide sequences that are capable of functioning as TCE's in the salmonid immune system. As tt P2 and MVF epitopes have been established as strong epitopes that exhibit promiscuous binding to various MHC haplotypes, these epitopes were incorporated onto the OspA fusion protein to elicit immunostimulatory effects. Although the incorporation of highly immunogenic promiscuous TCE's into chimeric fusion proteins to extend the immunostimulatory effect of toxoid carrier proteins on conjugated haptens is not *per se* novel, the immunostimulating effects of TCE's within the salmonid immune system is novel. Furthermore, the novelty of the immunostimulating effects of TCE's within teleosts is not dependent upon the identification and characterization of the outer surface lipoprotein OspA of *P. Salomonis*.

### Sequence Listing

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using

standard letter abbreviations for nucleotide bases, and one letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.

SEQ ID:1	shows the <i>ospA</i> DNA sequence from <i>P. salmonis</i>
SEQ ID:2	shows the amino acid sequence of the precursor (unprocessed) protein OspA
SEQ ID:3	shows the <i>ospA</i> DNA sequence, 17e2, modified for optimal codon usage in <i>E. coli</i>
SEQ ID:4	shows the amino acid sequence of the modified for optimal codon usage, in <i>E. coli</i> , precursor (unprocessed) protein OspA (17E2)
SEQ ID:5	shows the DNA sequence, c17e2, of an N-terminal fusion partner with optimized <i>ospA</i> gene
SEQ ID: 6	shows the amino acid sequence of an N-terminal fusion partner with optimized OspA (C17E2)
SEQ ID:7	DNA sequence of the forward oligonucleotide used during pTYB1-17kDa construction
SEQ ID:8	DNA sequence of the reverse oligonucleotide used during pTYB1-17kDa construction
SEQ ID:9	oligonucleotide #1 used for construction of optimized <i>ospA</i> gene, 17e2
SEQ ID:10	oligonucleotide #2 used for construction of optimized <i>ospA</i> gene, 17e2
SEQ ID:11	oligonucleotide #3 used for construction of optimized <i>ospA</i> gene, 17e2
SEQ ID:12	oligonucleotide #4 used for construction of optimized <i>ospA</i> gene, 17e2
SEQ ID:13	oligonucleotide #5 used for construction of optimized <i>ospA</i> gene, 17e2
SEQ ID:14	oligonucleotide #6 used for construction of optimized <i>ospA</i> gene, 17e2
SEQ ID:15	amino acid sequence of a 10 residue synthetic polypeptide based on residues 110-119 of OspA
SEQ ID:16	amino acid sequence of a 20 residue synthetic polypeptide based on residues 110-129 of OspA
SEQ ID:17	DNA sequence of the tt P2 TCE oligonucleotide
SEQ ID:18	DNA sequence of the MVF TCE oligonucleotide
SEQ ID:19	amino acid sequence of the tt P2 TCE
SEQ ID:20	amino acid sequence of the MVF TCE

### Brief Description of the Drawings

**Figure 1.** Western blot analysis of *P. salmonis*. Whole cell lysate and proteinase K digest samples of *P. salmonis* were separated by 12% SDS-PAGE and reacted with rabbit anti-*P. salmonis* polyclonal antibodies followed by immunochemical detection. Note the immunoreactive protein migrating at 17 kDa. The ~11 kDa antigen of *P. salmonis* was not susceptible to PK digestion. Molecular weights are in kDa.

**Figure 2. A.** Schematic of spatial relationships of ORF's in *P. salmonis* clone pB12, 4,983 bp. The *Xba* I and *Hind* III sites were used to subclone the *ospA* ORF into pBC(+) (Example 2). **B.** DNA sequence of the *P. salmonis ospA* ORF and amino acid sequence of the OspA protein translated from

the *ospA* ORF. **C.** Pairwise sequence alignment of the *P. salmonis* 17 kDa antigen, OspA, and the *R. prowazekii* 17 kDa antigen (SwissProt G112704). The pairwise alignment was generated using the FASTA3 algorithm. The *P. salmonis* 17 kDa antigen shares 41% identity (black background) and 62% similarity (black box) with the 17 kDa antigen of *R. prowazekii*. Synthetic peptides (SEQ ID:15, SEQ ID:16) representing the region from residues 110-129 of the *P. salmonis* 17 kDa antigen were used to generate rabbit polyclonal serum.

**Figure 3. A.** Map of pBC-17kDa, the pBC(+) plasmid encoding the subcloned *ospA* ORF (*Xba*I/*Hind* III fragment of clone pB12). Cm is chloramphenicol resistance, T7 is T7 promoter. **B.** Analysis of OspA expression. Whole cell lysates of *E. coli* clones and *P. salmonis* were analyzed by SDS-PAGE (12% polyacrylamide). *P. salmonis* whole cell lysate was reacted with rabbit polyclonal serum generated against a 10 residue peptide (SEQ ID:15) of OspA recognizing a strongly immunoreactive product in the 17 kDa region of *P. salmonis*. Expression of the OspA by clone pBC-17kDa was induced at 42°C and is visible stained by Coomassie blue. Rabbit polyclonal serum generated against a 20 residue peptide (SEQ ID:16) of OspA recognized the expressed 17 kDa protein in induced pBC-17kDa samples. Convalescent serum from coho salmon also recognized the induced 17 kDa protein in pBC-17kDa. Arrows identify the expressed 17 kDa antigen. Molecular weight standards are shown in kDa.

**Figure 4. A.** Schematic representation of the strategy employed during the synthesis of the *E. coli* codon optimized *ospA* gene, 17e2. **B.** DNA sequence of the 6 overlapping oligonucleotides used. **C.** DNA sequence of the *E. coli* codon optimized *ospA* gene, 17e2.

**Figure 5. A.** Amino acid sequence of the OspA protein, 17E2, expressed from the optimized *ospA* gene, 17e2. **B.** DNA sequence of the N-terminal *ospA* gene fusion construct, c17e2. **C.** Amino acid sequence of the OspA-fusion protein, C17E2, containing an N-terminal fusion.

**Figure 6. A.** Maps of the expression vectors encoding the optimized *ospA* fusion construct under the control of T7, pETC-17E2, and lambda promoters, pKLPR-C17E2. Ap is ampicillin resistance, Km is kanamycin resistance, T7 P is the T7 promoter, PLR is lambda right promoter. **B.** 12% polyacrylamide SDS-PAGE analysis of C17E2 expression. Samples from the lambda promoter expression represent the insoluble fraction (i.f.) of whole cells lysates. Whole cell (w.c.) samples from T7 expression are loaded along with a sample of the insoluble fraction. Note the abundant expression of the OspA-fusion product at 28.5 kDa in the induced samples. Molecular weight standards are shown in kDa.

**Figure 7.** Map of pTYB1-17kDa. An *ospA*-fusion construct encoding a C-terminal fusion partner was placed under the control of T7 promoter. The C-terminal fusion partner contained a self-cleaving spacer region and chitin binding domain.

**Figure 8. A.** A diagram illustrating the cloning strategy employed to create the OspA fusion protein constructs encoding promiscuous TCE's. 17E2 is the synthetic *ospA* gene that was created using codons optimized for *E. coli* high level expression. tt P2 and MVF are the DNA sequences

(SEQ ID:19, SEQ ID:20) encoding the tetanus toxin and measles virus fusion protein T cell epitopes (SEQ ID:17, SEQ ID:18). **B. (a)** Sequences of the tt P2 and **(b)** MVF oligonucleotides (SEQ ID:17, SEQ ID:18) used to incorporate the **(c)** tt P2 and **(d)** MVF TCE's (SEQ ID:19, SEQ ID:20) into the OspA fusion protein constructs. Bold nucleotides indicate the TCE coding region of the oligonucleotides.

**Figure 9.** Antibody titres of coho salmon groups against OspA-fusion protein candidate vaccines. Salmon were immunized with either C17E2, CT17E2, CM17E2, or CMT17E2. Antibody titres were defined as the maximum serum dilution that resulted in a signal corresponding to 3 times the background obtained with the diluent vaccinated serum group at a dilution of 1:320.

**Figure 10.** Proliferative lymphocyte responses of vaccinated Atlantic salmon (*Salmo salar*). The highest lymphocyte stimulation occurred in salmon that were vaccinated with an OspA fusion protein containing two promiscuous TCE's (CMT17E2).

**Figure 11.** Vaccine trial of OspA fusion protein constructs containing promiscuous TCE's in an outbred population of coho salmon. Adjuvant-injected salmon experienced a cumulative mortality of 85.5% when challenged with *P. salmonis* by IP injection. C17E2 vaccinated salmon reached a cumulative mortality of 59.6%. CT17E2 vaccinated salmon experienced 35.6% cumulative mortality. CM17E2 and the CM17E2 + CT17E2 groups experienced 20 and 18.6% cumulative mortality, respectively. The CMT17E2 vaccinated group experienced only 14.5% cumulative mortality. RPS values of C17E2, CT17E2, CM17E2, CM17E2 + CT17E2, and CMT17E2 were 30.2, 58.4, 76.6, and 83.0%, respectively.

## Detailed Description of the Invention

### I. Definitions

**Epitope:** An epitope refers to an immunologically active region of an immunogen (most often a protein, but sometimes also a polysaccharide or lipid) that binds to specific membrane receptors for antigen on lymphocytes or to secreted antibodies. To generate an immune response to a foreign antigen, lymphocytes and antibodies recognize these specific regions (epitopes) of the antigen rather than the entire molecule.

**B cell epitope:** The region (epitope) of an immunogen which is recognized by B cells when it binds to their membrane bound antibody. The B cells which recognize that particular region then proliferate and secrete antibody molecules which are specific for that region of the immunogen. B cell epitopes tend to be highly accessible regions on the exposed surface of the immunogen. Stimulation of the immune system by B cell epitopes results in "humoral" immunity.

**T cell epitope:** The region (epitope) of an immunogen which is recognized by a receptor on T cells after being processed and presented on the surface of an antigen presenting cell (APC) in the context of a major histocompatibility complex (MHC) class I or II molecule. T cells can be split into two



distinct groups, T helper cells ( $T_h$ ) and T cytotoxic cells ( $T_c$ ). T helper cells recognize epitopes bound to MHC class II molecules whereas T cytotoxic cells recognize epitopes bound to MHC class I molecules. T helper cells can be further subdivided into two classes,  $T_{h1}$  and  $T_{h2}$ ,  $T_{h1}$  being responsible for stimulation of cell-mediated immunity and  $T_{h2}$  cells stimulating the humoral arm of the immune system. When a given T cell recognizes the epitope-MHC complex at the surface of the APC it becomes stimulated and proliferates, leading to the production of a large number of T cells with receptors specific for the stimulating epitope. Stimulation of the immune system by T cell epitopes normally results in “cell-mediated” immunity.

**Attenuated Bacterial Vaccine:** This refers to bacterial strains which have lost their pathogenicity while retaining their capacity for transient growth within an inoculated host. Because of their capacity for transient growth, such vaccines provide prolonged immune-system exposure to the individual epitopes on the attenuated organisms, resulting in increased immunogenicity and memory-cell production, which sometimes eliminates the need for repeated booster injections. The ability of many attenuated vaccines to replicate within host cells makes them very suitable to induce a cell-mediated immunity. Typically, bacterial strains are made attenuated by introducing multiple defined gene mutations into the chromosome thereby impairing growth *in vivo*.

**Recombinant Vector Vaccine:** This refers to the introduction of genes (or pieces of genes) encoding major antigens (or epitopes) from especially virulent pathogens into attenuated viruses or bacteria. The attenuated organism serves as a vector, replicating within the host and expressing the gene product of the pathogen.

**Sequence Identity:** Identity between two nucleic acid sequences, or two amino acid sequences is expressed in terms of the level of identical residues shared between the sequences. Sequence identity is typically expressed in terms of percentage identity; the higher the percentage, the more similar the two sequences are.

**Sequence Similarity:** Similarity between two amino acid sequences is expressed in terms of the level of sequence conservation, including shared identical residues and those residues which differ but which share a similar size, polarity, charge or hydrophobicity. Sequence similarity is typically expressed in terms of percentage similarity; the higher the percentage, the more similar the two sequences are.

**Recombinant:** A recombinant nucleic acid is one that has a sequence that is not normally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.

**Oligonucleotide (oligo):** A linear polymer sequence of up to approximately 100 nucleotide bases in length.

**Probes and primers:** Nucleic acid probes and primers may readily be prepared based on the amino acid and DNA sequence provided by this invention. A probe comprises an isolated nucleic acid attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed, e.g., in Sambrook et al.

Primers are short nucleic acids, preferably DNA oligonucleotides 15 nucleotides or more in length. Primers may be annealed to a complementary target DNA strand, and then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art.

Methods for preparing and using probes and primers are described, for example, in Sambrook, 1989, Ausubel, 1987, and Innis, 1990. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as DNASTar Lasergene software. One of skill in the art will appreciate that the specificity of a particular probe or primer increases with its length. Thus, for example, a primer comprising 20 consecutive nucleotides will anneal to a target with a higher specificity than a corresponding primer of only 15 nucleotides. Thus, in order to obtain greater specificity, probes and primers may be selected that comprise 20, 25, 30, 35, 40, 50 or more consecutive nucleotides.

**Isolated:** An "isolated" biological component (such as nucleic acid or protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, i.e., other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles. Nucleic acids and proteins that have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids. An "isolated" bacterial strain or colony is purified away from other colonies and yields a pure culture without any contaminants upon plating on selective media.

**Vector:** A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the art. A "temperature-sensitive" vector is one which replicates normally at a low growth temperature (i.e., 28°C) and will not replicate at a higher growth temperature (i.e., 42°C) due to mutations at or near the origin of replication. An "imperfectly segregating" vector is one which is not stably inherited by new daughter cells at the time of cell division in the absence of selection pressure due to mutations within the vector sequence.

**Host Cell:** Refers to those cells capable of growth in culture and capable of expressing OspA protein and/or OspA fusion protein. The host cells of the present invention encompass cells in *in vitro* culture and include prokaryotic and eukaryotic, including insect cells. A host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene

product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers (i.e. temperature, small inducer molecules such as  $\beta$ -galactosides for controlling expression of T7 or *lac* promoters or variants thereof). The preferred host cell for the cloning and expression of the OspA protein and OspA-fusion protein is a prokaryotic cell. An example of a prokaryotic cell useful for cloning and expression of the OspA protein of the present invention is *E. coli* BL21.

**Cell Culture:** **(a)** Refers to the growth of eukaryotic (non-bacterial) cells in a complex culture medium generally consisting of vitamins, buffers, salts, animal serum, and other nutrients. **(b)** Refers to the growth of *P. salmonis* on CHSE-214 and any other cell line that sustains *P. salmonis* growth.

**Fusion Partner:** Any DNA sequence cloned in frame to the 5' or 3' end of an ORF that results in transcription and translation of amino acid sequence added to the N- or C-terminus of the original protein.

**Fusion Protein:** The term fusion protein used herein refers to the joining together of at least two proteins, an OspA protein and a second protein. In some embodiments of the present invention, the second protein may be fused or joined to a third protein. In the present invention, examples of second proteins include any polypeptide that facilitates the following: expression, secretion, purification, condensation, precipitation, or any property which facilitates concentration or purification.

**Variant:** Any molecule in which the amino acid sequence, glycosylation, phosphorylation, and/or lipidation pattern, or any other feature of a naturally occurring molecule which has been modified covalently or non-covalently and is intended to include mutants. Some of the variants falling within this invention possess amino acid substitutions, deletions, and/or insertions provided that the final construct possesses the desired ability of OspA. Amino acid substitutions in OspA may be made on a basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Also included within the definition of variant are those proteins having additional amino acids at one or more of the C-terminal, N-terminal, and within the naturally occurring OspA sequence as long as the variant protein retains the desired capability of OspA to act as an antigen and hence as a vaccine.

<u>Original Residue</u>	<u>Conservative Substitutions</u>
Ala	ser
Arg	lys
Asn	gln; his
Asp	glu
Gln	asn
Glu	asp
Gly	pro
His	asn; gln

Ile	leu; val
Leu	ile; val
Lys	arg; gln; glu
Met	leu; ile
Phe	met; leu; tyr
Ser	thr
Thr	ser
Trp	tyr
Tyr	trp; phe
Val	ile; leu

Table 1: More substantial changes in functional or other features may be obtained by selecting substitutions that are less conservative than those in Table 1, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in protein properties will be those in which (a) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine. Variant proteins having one or more of these more substantial changes may also be employed in the invention, provided that immunogenicity of OspA is retained.

More extensive amino acid changes may also be engineered into variant OspA. As noted above however, these variants will typically be characterized by possession of at least 40% sequence identity counted over the full length alignment with the amino acid sequence of their respective naturally occurring sequences using the alignment programs described herein. In addition, these variant OspA proteins would retain immunogenicity.

Confirmation that OspA has immunogenic activity may be achieved using the immunological and protection experiments described herein. Following confirmation that OspA has the desired immunogenic effect, a nucleic acid molecule encoding OspA may be readily produced using standard molecular biology techniques. Where appropriate, the selection of the open reading frame will take into account codon usage bias of the bacterial or eukaryotic species in which OspA is to be expressed.

**Inclusion body:** Intracellularly confined, insoluble, protein-containing particles of bacterial cells comprised of either homologous or heterologous proteins. These particles are the reservoirs and consequence of overproduction of bacterial recombinant proteins. Inclusion bodies can be purified

or semi-purified and used directly as protein antigens or can be solubilized by various procedures and used as soluble protein antigen preparations.

**Alignment programs:** Methods for aligning sequences for comparison purposes are well known in the art. Various programs and alignment algorithms are described in Smith and Waterman (1981), Needleman and Wunsch (1970), Pearson and Lipman (1988), Higgins and Sharp (1988, 1989), Corpet *et al.* (1988), Huang *et al.* (1992), Pearson *et al.* (1994). Altschul *et al.* (1990) presents a detailed consideration of sequence alignment methods.

The National Centre of Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST; Altschul *et al.*, 1990) is available from several sources, including the NCBI (Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs BLASTP, BLASTN, BLASTX, TBLASTN, TBLASTX. BLAST can be accessed at <http://www.ncbi.nlm.nih.gov/BLAST/>. A description of how to determine sequence identity using this program is available at [http://www.ncbi.nlm.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nlm.nih.gov/BLAST/blast_help.html).

For comparisons of amino acid sequences of greater than 30 amino acids, the "BLAST 2 Sequences" function in the BLAST program is employed using the BLASTP program with the default BLOSUM62 matrix set to default parameters, (open gap 11, extension gap 1 penalties). When aligning short peptides (fewer than 30 amino acids), the alignment should be performed using the "Blast 2 Sequences" function employing the BLASTP program with the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins having even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 45%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% sequence identity.

**Promoter:** A region of DNA to which either RNA polymerase or any other enhancer protein binds before initiating transcription of the DNA code into the RNA gene product. For example; lambda, phage T7, *lac*, *tac*, *srpP*, *trpP*, or *araB* etc. promoter DNA. A promoter region therefore determines the efficiency of the RNA gene product.

**Fragments:** Those parts of either the DNA encoding a gene for a protein, a TCE, or a fusion partner and those parts of the protein, TCE, or fusion partner itself.

## II. Selection and Creation of Nucleic Acid Sequences Encoding the 17 kDa OspA Protein

### a. Growth & Purification of *P. salmonis*

*P. salmonis* strains were routinely passaged on chinook salmon embryo cell line CHSE-214 (ATCC CRL-1681) at 17°C in Eagle's minimal essential media (MEM) with Earle's salts supplemented with 10% newborn calf serum. Type strain *P. salmonis* LF-89 was obtained from the American Type Culture Collection (ATCC VR-1361) and is herein referred to as *P. salmonis*.

A protocol for purifying *P. salmonis* was developed by combining and modifying the protocols of Tamura *et al* (Tamura, *et al.*, 1982) and Weiss *et al* (Weiss, *et al.*, 1975). A 6,320 cm<sup>2</sup> Nunc cell factory was seeded with cell line CHSE-214 and infected with 450 ml of cell culture supernatant from fully lysed CHSE-214 monolayers infected with *P. salmonis*. Infection was allowed to continue 14-17 days until cytopathic effects obliterated the entire monolayer. Upon destruction of the monolayers cell culture supernatants were collected and centrifuged at 10,000 × g for 30 min at 4°C. Pellets were resuspended in MEM and homogenized in a 15 ml Dounce tissue homogenizer.

The homogenized suspension was centrifuged at 200 × g for 10 min at 4°C to pellet large host cell debris. The supernatant was filtered twice through glass microfibre and centrifuged at 17,600 × g for 15 min at 4°C. Pellets were resuspended in TS-buffer (33 mM Tris-HCl, 0.25 M sucrose; pH 7.4). Samples were loaded onto Percoll gradients with a final concentration of 40% and centrifuged in a fixed angle rotor (type JA-14) at 20,000 × g for 60 min at 4°C in a Beckman J2-21 centrifuge. Bands were collected by aspiration, diluted with phosphate buffered saline, pH 7.4 (Sambrook, *et al.*, 1989) and centrifuged at 20,000 × g for 10 min at 4°C. Pellets were washed twice with phosphate buffer solution (PBS). Contents of the bands were negative stained with 0.5% phosphotungstic acid and analyzed by transmission electron microscopy on a Phillips EM 300 at an accelerating voltage of 75 kV.

#### **b. Demonstration of Immunoreactive Molecules**

In order to characterize the antigenic profile of *P. salmonis*, western blot analysis was carried out using anti-*P. salmonis* rabbit serum (Fig. 1). Proteinase K digestion was used to determine if any observed antigens may have been carbohydrate. Six *P. salmonis* immunoreactive antigens were observed at relative molecular weights of 65, 60, 54, 51, 17, and 11 kDa (Fig. 1). Proteinase K digestion destroyed all immunoreactive antigens except the 11 kDa antigen (Fig. 1).

#### **c. Purification of Genomic DNA & Construction of Library**

*P. salmonis* was purified by density gradient centrifugation as previously described (Kuzyk, *et al.*, 1996) from 12,000 cm<sup>2</sup> of CHSE-214 cells exhibiting full cytopathic effect 14 days after infection with *P. salmonis*. A single step DNA isolation solution was used to obtain genomic DNA from the purified *P. salmonis*. Genomic DNA was further purified by equilibrium centrifugation using a CsCl-ethidium bromide gradient to yield 250 µg of *P. salmonis* genomic DNA (Sambrook, *et al.*, 1989).

*P. salmonis* DNA was partially digested using serially diluted *EcoR* I. Digests containing an average fragment size of 10 kb were chosen for creation of a *P. salmonis* gene expression library using a lambda ZAP II cloning kit.

#### **d. Immunological Screening of Library**

Approximately 10,000 plaques of *P. salmonis* lambda expression library were screened per round with a desired density of 1,000 plaques per 80 mm petri dish. Plaques were lifted in duplicate using

80 mm nitrocellulose discs impregnated with 10 mM isopropyl- $\beta$ -D-thiogalactoside (IPTG). Screening followed the protocol of Sambrook *et al.* (1989) using anti-*P. salmonis* rabbit serum. Immunoreactive plaques were picked and rescreened until pure cultures were obtained. Lambda clones were then amplified and the pBluescript phagemid excised into *E. coli*.

Screening of the *P. salmonis* expression library with high titre anti-*P. salmonis* rabbit serum identified several strongly immunoreactive plaques. These plaques were picked and rescreened until pure and were confirmed to contain inserts. Initial attempts to excise the clones into *E. coli* from the lambda clones were unsuccessful which suggested the clones may encode products toxic to *E. coli*. Restriction fragment length analysis using frequently cutting enzymes suggested that all clones contained a common region of DNA. The clones contained a 5 kb insert (Example 1).

Genomic DNA from all the lambda clones, *P. salmonis*, CHSE-214, and vector plasmid DNA was analyzed by DNA dot blotting using insert DNA from one clone (Clone pB12) as the probe. Hybridization revealed that the pB12 insert was of *P. salmonis* origin. The pB12 insert also hybridized with all other immunoreactive lambda clone samples indicating that all the inserts encoded an overlapping fragment of *P. salmonis* DNA.

### e. DNA Sequence Analysis of Clone pB12

DNA sequence analysis of clone pB12 (Example 1) identified 4 complete ORF's within the 4,983 bp insert and 1 partial ORF (Example 1). The predicted amino acid sequences of these ORF's was subjected to homology searches using alignment programs (eg. BLAST2 and FASTA3). No significant matches were found when searching for DNA sequence homology to the pB12 insert. The 499 bp 'alr' ORF (Example 1) was predicted to encode a 176 residue (res.) protein fused to the N-terminus of LacZ. The predicted molecular weight (m.w.) of the LacZ-'Alr' fusion is 22.2 kDa. The predicted 'Alr' ORF amino acid sequence shares 44% identity and 63% similarity with C-terminal portions of known alanine racemase enzymes from *Klebsiella aerogenes* (GenBank AAC38140), *Salmonella typhimurium* (GenBank A29519), and *E. coli* (GenBank BAA36048).

A 732 bp ORF (*bax*; Example 1) was predicted to encode a 243 res., 27.6 kDa protein. Both FASTA3 and BLAST2 only identified low scoring similarity (33% identical, 49% similar) between the central 187 amino acid region of the *bax* ORF and a 274 res. uncharacterized, hypothetical protein in *E. coli* K12 (BAX; GenBank AAB18547).

A 1368 bp ORF (*radA*; Example 1) was predicted to encode a 456 res., 49.4 kDa protein. A high degree of amino acid homology was found over the entire length of the *radA* ORF and RadA DNA repair enzymes from a variety of bacteria. *P. salmonis* RadA is most homologous to RadA of *Pseudomonas aeruginosa* (SwissProt P96963) with 62% identity and 77% similarity. *P. salmonis* RadA also exhibits 59% identity and 75% similarity to *E. coli* RadA (SwissProt P24554).

A 486 bp ORF (*ospA*; Example 1), immediately following *radA*, was predicted to encode a 162 res., 17.7 kDa protein with amino acids 21-162 having substantial sequence similarity with the mature

chain of the rickettsial 17 kDa genus common antigen. The predicted 17 kDa antigen was up to 41% identical and 62% similar to the 17 kDa protein antigens of *R. prowazekii* (SwissProt G112704), *Rickettsia japonica* (SwissProt Q52764), *Rickettsia rickettsii* (SwissProt P05372), and *Rickettsia typhi* (SwissProt P22882). The 17 kDa protein of rickettsiae is translated as a precursor protein containing a 20 amino acid signal peptide. During processing the signal peptide is removed and the N-terminal cysteine residue is lipid-modified to form the mature protein. The first 21 amino acids of the *P. salmonis* OspA protein are predicted to be a signal peptide and contain a bacterial lipidation pattern as well.

The final 717 bp ORF (*tnpA*; Example 1) was predicted to encode a 239 res., 27.7 kDa protein. This ORF is flanked by a perfect 288 bp direct repeat. Amino acid similarity searches returned strong matches between the *tnpA* ORF and a variety of transposases. The closest match was a transposase (GenBank U83995) in a *Porphyromonas gingivalis* insertion element, IS195, with 47% identity and 65% similarity (Lewis and Macrina, 1998).

#### **f. Identification of the *ospA* ORF as the 17 kDa Antigen**

Rabbit antibodies raised against 10-mer and 20-mer synthetic peptides of this region reacted with an immunoreactive product in *P. salmonis* around the 17 kDa predicted mass of the *ospA* ORF product (Example 2). Expression of the 17 kDa antigen was induced in clone pBC-17kDa and was recognized by rabbit serum against the synthetic peptides (Example 2). Serum from coho salmon fry that had survived a challenge with *P. salmonis* also recognized the induced 17 kDa product (Example 2). These data confirm that the *ospA* ORF encodes the immunoreactive 17 kDa OspA antigen.

#### **g. Optimization of the *ospA* ORF for *E. coli* Expression**

The coding sequence of *ospA* was optimized using codons used frequently by *E. coli* (Example 3). Six overlapping oligonucleotides representing the optimized *ospA* gene were synthesized using standard phosphoramidite method. The gene was assembled using 2 successive PCR reactions with the oligonucleotides and the full length product was cloned into an appropriate cloning vector. DNA sequence of the optimized *ospA* gene was verified by sequence analysis using an automated sequencer. Production of the OspA protein from the optimized *ospA* gene was confirmed upon subcloning the optimized *ospA* gene to the pET21(+) (Novagene) expression vector and inducing expression using the T7 promoter (Example 3).

#### **h. Description of the Fusion Protein Constructs**

The level of OspA production from the optimized *ospA* gene was still relatively low. It is well known to persons skilled in the art that fusion partners can aid in increasing the level of production of proteins. We constructed both N- and C-terminal fusions (Examples 4 & 5) with the *ospA* gene. In our examples we show that some fusions resulted in increased production of the OspA-fusion with the N-terminal fusion partner being more favourable than the C-terminal fusion partner. It is possible



that presence of a signal peptide on the N-terminus of OspA may hamper high level production of OspA. Therefore, the N-terminal fusion partner may increase OspA production by masking the signal peptide. Similar increases in OspA production may be obtained from deletion of the region of the *ospA* gene that encodes the signal peptide.

TCE's tt P2 (SEQ ID 17) and MVF (SEQ ID 18) were synthesized as oligonucleotides using codons optimized for high level expression in *E. coli*. The epitope coding regions of the MVF and tt oligonucleotides were flanked by *Bam*H I, *Nde* I and *Vsp* I, *Hind* III restriction endonuclease sites and primer binding sites for subsequent PCR amplification and subcloning. The MVF and tt P2 oligonucleotides were converted to double stranded DNA and amplified by PCR using standard conditions (Giovannoni, 1991) and cloned into pBC-V using *Bam*H I and *Hind* III restriction endonuclease sites to create pBC-MVF and pBC-ttP2. Vector pBC-V is a variant of pBC KS(+) that lacks *Vsp* I restriction endonuclease sites at 925 and 984 bp. pBC KS(+) was digested with *Vsp* I, single stranded ends were filled in using Klenow fragment, and blunt end ligation was performed to create pBC-V.

The *Bam*H I and *Vsp* I fragments of pBC-MVF and pBC-ttP2 were separately subcloned into the *Bam*H I and *Nde* I sites of pET-C17E2 (Fig. 8). This subcloning step placed the TCE's in frame between *ospA* and the N-terminal fusion partner to create pET-CM17E2 and pET-CT17E2 (Fig. 8). Ligation of the *Vsp* I and *Nde* I cohesive ends destroyed the respective restriction sites while an *Nde* I site was encoded in the 5'-terminal region of the TCE insert to allow subsequent ligation of inserts in frame and upstream of the TCE using *Bam*H I and *Nde* I (Fig. 8).

A third construct encoding both TCE's was created by subcloning the *Bam*H I and *Vsp* I fragment of pBC-MVF into the *Bam*H I and *Nde* I sites of pET-CT17E2 to create pET-CMT17E2 (Fig. 8).

## EXAMPLES

The following examples are included to demonstrate preferred embodiments of the invention, and it will be appreciated by those skilled in the art, in light of this disclosure, that many changes can be made in the specific embodiments disclosed without departing from the scope of the invention.

### 1. Sequence Analysis of *P. salmonis* Insert Producing Immunoreactive Material

A directional deletion library of *P. salmonis* clone pB12 was constructed to facilitate sequence analysis. *Exo* III and S1 nuclease were used to construct double-stranded nested deletions in the direction of *lacZ*. Restriction endonucleases *Eco*R I and *Sac* I were used to generate opposing overhangs protecting the vector from *Exo* III digestion. Upon ligation and screening, 32 deletion clones were selected that represented the entire insert and differed in size by 100-500 bp.

Double stranded plasmid DNA samples were sequenced using a combination of dye primer and dye termination. Sequencing reactions were analyzed using an automated DNA sequencer. Sequence data were assembled and analyzed using commercially available computer software packages.

DNA sequencing of pB12 *Exo* III/S1 nuclease deletion clones revealed that the insert was 4,983 bp. Coding predictions identified 4 intact ORF's and 1 partial ORF creating a fusion in frame with LacZ

(Fig. 2). The predicted ORF's were subjected to BLAST2 (Altschul, *et al.*, 1997) and FASTA3 (Pearson, 1998) analysis to determine if any similar sequences were known (Fig. 2).

## 2. Identification of the *ospA* ORF as the Source of OspA

Residues 110-129 of the 17 kDa antigen encoded by the predicted *ospA* ORF were predicted to be a B cell epitope by the Jameson-Wolf method (Jameson and Wolf, 1988). Antibodies were generated in New Zealand white rabbits against 10 and 20 amino acid synthetic peptides (SEQ ID:15; SEQ ID:16) representing amino acids 110-129 of the predicted OspA amino acid sequence (SEQ ID:2). Peptides were glutaraldehyde conjugated to for 1 h at 4°C in a 10 ml reaction volume with 500 µg/ml keyhole limpet hemocyanin and 1% glutaraldehyde. For the primary immunization, rabbits received 250 µg of conjugated peptide mixed 1:1 with Freund's complete adjuvant. Each rabbit was boosted three times at 2 week intervals with 250 µg of conjugated peptide per boost mixed 1:1 with Freund's incomplete adjuvant.

**Table 2:** Synthetic polypeptides used to generate polyclonal rabbit antibodies against OspA.

Peptide	Sequence
10 mer (SEQ ID:15)	Pro-Val-Arg-Thr-Tyr-Gln-Arg-Tyr-Asn-Lys
20 mer (SEQ ID:16)	Pro-Val-Arg-Thr-Tyr-Gln-Arg-Tyr-Asn-Lys-Gln-Glu-Arg-Arg-Gln-Gln-Tyr-Cys-Arg-Glu

The 17 kDa antigen *ospA* ORF was subcloned into pBC(+) under control of the T7 promoter. The *Xba* I/*Hind* III fragment of clone pB12 was ligated with *Xba* I/*Hind* III digested pBC(+) to generate clone pBC-17kDa. Induction of the T7 promoter by shifting growth temperature to 42°C resulted in expression of a 17 kDa protein observed by Coomassie staining of whole cell lysates of induced clone pBC-17kDa SDS-PAGE samples (Fig. 3). Western blot analysis of whole cell lysates of *P. salmonis* and pBC-17kDa with rabbit antibodies generated against synthetic peptides of OspA reacted with a 17 kDa protein in both *P. salmonis* and the induced sample of pBC-17kDa confirming the *ospA* ORF as the source of then translated OspA protein (Fig. 3).

## 3. Synthesis & Cloning of Optimized *ospA* Gene

A nucleic acid molecule was designed to encode the OspA protein precursor (OspA including signal peptide). This nucleic acid was constructed by PCR using 6 overlapping oligonucleotides (SEQ ID:9, SEQ ID:10, SEQ ID:11, SEQ ID:12, SEQ ID:13, and SEQ ID:14). Synthesis of *ospA* gene was done by three subsequent PCR using the six synthetic overlapping oligonucleotides (Fig. 4A & Fig. 4B). PCR-1 involved overlapping oligonucleotides SEQ ID:11, SEQ ID:12 (0.05 pmol/µl each) and SEQ ID:10, SEQ ID:13 (0.25 pmol/µl each). Product of PCR-1 (1 µl) was used as a template in PCR-2 using oligonucleotides SEQ ID:9 and SEQ ID:14 as primers (0.25 pmol/µl). Both PCR were

performed using *Taq* I polymerase (Boehringer), supplied buffer and deoxynucleotide triphosphates (dNTP) (Amersham Pharmacia). Temperature cycling was as follows: PCR-1 & 2: 92°C 30 sec

92°C 30 sec., 70°C 30 sec., 72°C 30 sec., 29 cycles

Product of PCR2 (Fig. 4C) was cloned into plasmid vector pBC(+) as a *Bam*H I – *Hind* III fragment resulting to pBC-17E2. DNA sequence of the insert was verified by DNA sequencing using methods known to those skilled in the art. The DNA fragment of pBCKS-17E2 carrying optimized *ospA* gene was then cloned to pET21(+) as a *Nde* I – *Hind* III DNA fragment resulting to pET-17E2.

#### 4. Expression of Optimized *OspA* Antigen With N-Terminal Fusion Partner

##### A. Expression using T7 promoter system

DNA fragment of pBCKS-17E2 carrying optimized *ospA* gene was cloned, using methods known to one skilled in the art, to pETC (Microtek International) resulting to pETC-17E2 as a *Bam*HI-*Hind*III fragment carrying *ospA* fused to a desired fusion partner under control of T7 promoter (Fig. 5, Fig. 6A).

Strain *E. coli* BL21 [*E. coli* B, F<sup>-</sup>, *ompT*, *hsdS* (*r*<sub>S</sub><sup>-</sup>, *m*<sub>S</sub><sup>-</sup>), *gal*, *dcm*] (Pharmacia) carried the recombinant expression plasmid pETC-17E2 and helper plasmid pGP1-2 (Tabor and Richardson, 1985). Expression experiment was performed in 4 L flask. During the growth phase, the culture was grown in Terrific Broth (TFB) with agitation (~300 RPM) at 28-30°C to late log phase. Then cells were diluted with an equal volume of fresh TFB media and growth continued at 42°C 3-6 hours. Product was accumulated inside cells as insoluble aggregates of protein. Cells from 1 ml of culture were sedimented in a microcentrifuge, washed with water, resuspended in 1 ml of water and disrupted by sonication. Insoluble material was sedimented, washed with water and analyzed by 15% SDS-PAGE as is known to one skilled in the art (Fig. 6B).

##### B. Expression using lambda promoter system

DNA fragment of pETC-17E2 carrying fused optimized *ospA* gene was subcloned, using methods known to one skilled in art, to pKLPR-8 (Microtek International 1998 Ltd.) resulting in pKLPR-C17E2 as a *Xba* I – *Kpn* I fragment carrying the *ospA* fusion under control of phage lambda promoter. Plasmid also carries repressor gene CI875 of the lambda promoter (Fig. 5).

Strain *E. coli* BL21 [*E. coli* B, F<sup>-</sup>, *ompT*, *hsdS* (*r*<sub>S</sub><sup>-</sup>, *m*<sub>S</sub><sup>-</sup>), *gal*, *dcm*] (Pharmacia) carried the recombinant expression plasmid pKLPR-C17E2 (Fig. 6A). During the growth phase, the culture was grown in TFB with agitation (300 RPM) at 28-30 °C to late log phase. Then cells were diluted with an equal volume of fresh TFB media and growth continued at 42°C 3-6 hours. Product was accumulated inside cells as insoluble aggregates of protein. Cells from 1 ml of culture were sedimented in a microcentrifuge, washed with water, resuspended in 1 ml of water and disrupted by sonication. Insoluble material was sedimented, washed with water and analyzed by 15% SDS-PAGE as is known to one skilled in the art (Fig. 6B).

### 5. Expression of Optimized OspA Antigen With C-Terminal Fusion Partner

The *P. salmonis* *ospA* ORF was subcloned into the Impact CN Expression System (New England Biolabs) to add a C-terminal fusion partner containing a self-cleaving spacer region and chitin binding domain to aid in purification and antibody generation of OspA (Fig. 7).

The *ospA* ORF was PCR amplified from clone pB12 using custom primers (Table 3) designed to incorporate *Nde* I and *Sap* I restriction enzyme cleavage sites onto the 5' and 3' ends of the *ospA* ORF. The *ospA* PCR product was digested with *Nde* I and *Sap* I restriction enzymes and ligated with the pTYB1 vector (NEB) of the Impact CN system digested with *Nde* I and *Sap* I to create the OspA fusion construct, pTYB1-17kDa (Fig. 7). Positive clones were identified by screening *Kpn* I and *Nde* I digests of plasmid preps from potential positive clones by agarose gel electrophoresis. Positive clones were confirmed to contain the *ospA* ORF in frame with the chitin binding domain by DNA sequence analysis.

**Table 3:** Oligonucleotide primers used during construction of pTYB1-17kDa. Bold nucleotides are not homologous to the template *ospA* ORF.

Primer	Sequence
Forward (SEQ ID:7)	5' – GAG AGA ACA TAT GAA CAG AGG ATG TTT GCA AGG – 3'
Reverse (SEQ ID:8)	5' – GCC ATA AGC TCT TCC GCA TTT TTC TGT TGA AAT GAC TTG C – 3'

### 6. Salmonid Antibody Response to OspA-fusion Vaccine

Coho salmon antibody response to the OspA with N-terminal fusion partner vaccine candidate (Example 4) was assayed by enzyme linked immunosorbant assay (ELISA). Coho salmon fry (125 per group; ~15 g mean weight) were each injected intraperitoneally (IP) 0.2 ml of a formalin inactivated (1 ml/L) adjuvanated (Microgen™) vaccine (5:1 vaccine:adjuvant) containing 50 µg of total protein purified as the insoluble fraction from *E. coli* BL21 expressing the *ospA* fusion construct pET-C17E2 (Example 4). A control group of fish received 0.2 ml of adjuvant diluted with saline 5:1. A second control group was comprised of non-vaccinated salmon.

Four weeks post-immunization, 5 fish from each group were bled from the caudal vein, kept on ice, blood was pooled for each group and serum was collected by centrifugation of pooled blood at 5,000 rpm for 20 min in a clinical centrifuge. ELISA plates were coated with 10 µg of C17E2 protein in 100 µl of coating buffer (Tris buffered saline (TBS), pH 7.5, 0.5% Tween-20). Plates were covered with parafilm and incubated at 4°C overnight. Coating solution was removed and wells were blocked with 200 µl of Tween-TBS with 3% bovine serum. Plates were washed 3 times with Tween-TBS. Fish serum from each group was serially diluted in Tween-TBS with 3% bovine serum and added to wells. Plates were then incubated at 15°C for 1 h and then washed 3 times with Tween-TBS. Second antibody, a mixture of 2 monoclonal antibodies (mAb) against salmon immunoglobulin, IPA2C7 (dil. 1/100) and Beecroft (dil. 1/500), were diluted in Tween-TBS with 3% bovine serum, added to plates and incubated at room temperature for 1 h. Plates were washed 3 times with TBS-Tween. Third antibody, alkaline phosphatase conjugated goat anti-mouse IgG<sub>1</sub> (dil. 1/2000), was

added to plates and incubated at room temperature for 1 h. Plates were washed 3 times. The ELISA was developed with 100  $\mu$ l of 1 mg/ml para-nitrophenyl phosphate in alkaline phosphatase buffer and incubated at room temperature overnight and absorbance at 405 nm was measured spectrophotometrically.

Antibody titres were defined as the maximum serum dilution that resulted in a signal corresponding to 3 times the background obtained with the diluent vaccinated serum group at a dilution of 1:320. Background serum was pooled from coho salmon vaccinated with adjuvant alone at each time point. The results indicate that all OspA fusion protein constructs are capable of eliciting an antibody response in immunized coho higher than the response obtained with adjuvant alone. The highest antibody responses were found in coho salmon immunized with OspA fusion proteins containing promiscuous TCE's (Fig. 9).

## 7. Salmonid Lymphocyte Response to OspA-fusion Vaccine

The lymphocyte response to the OspA-fusion protein vaccine constructs was measured using the lymphocyte proliferation assay.

**Isolation of lymphocytes.** Atlantic salmon that had been vaccinated 4 weeks prior with 0.2 ml of each OspA fusion protein vaccine were euthanized with an overdose of marinil and their head kidneys were aseptically harvested and immediately placed in 5 ml of cold MEM-10 (10% fetal bovine serum; Life Technologies) on ice. All subsequent manipulations were conducted on ice. Cells were dissociated by repeated passage through a 5 ml syringe. The tissue suspension was placed in a 15 ml tube and 7 ml of additional MEM-10 were added. Tissue fragments were allowed to settle out of solution for 10 min. Cells suspended in the media were collected and layered on 4 ml of 51% Percoll (10 ml 10 $\times$  HBSS, 51 ml Percoll, made up to 100 ml with H<sub>2</sub>O). The step gradient was centrifuged for 30 min at 400  $\times$  g, 4°C. Lymphocytes were collected from the MEM-10/Percoll interface. Lymphocytes were centrifuged and washed once in MEM-10 and resuspended in 1 ml MEM-10. The numbers of viable cells was determined using Trypan blue (0.4%; Sigma) staining. Cells were diluted to a final concentration of 5  $\times$  10<sup>6</sup> cells/ml with MEM-10.

**Lymphocyte proliferation assay.** Isolated lymphocytes were added to 96 well cell culture plates with 5  $\times$  10<sup>5</sup> cells/well (100  $\mu$ l vol.). OspA fusion protein C17E2 was added as a stimulating antigen (2  $\mu$ g/well) and cells were incubated for 6 days at 17°C. Lymphocyte proliferation was determined spectrophotometrically using WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) cell proliferation reagent (Roche Molecular Biochemicals). WST-1 allows colorimetric quantification of cell proliferation based on cleavage of WST-1 by mitochondrial dehydrogenases in viable cells. WST-1 (10  $\mu$ l) was added to each well and plates were incubated at 17°C until sufficient colour development prior to absorbance measurement at 450 nm with a reference wavelength of 630 nm. Bacterial lipopolysaccharide (LPS) (100  $\mu$ g/ml) and concanavalin A (ConA) (50  $\mu$ g/ml) were used as B and T lymphocyte mitogens for positive controls.

The degree of lymphocyte stimulation was determined by calculating the stimulation index for each sample of lymphocytes exposed to antigen (Fig. 10). Stimulation index was calculated by dividing

the average absorbance of lymphocyte samples presented with stimulating antigen by the average absorbance of lymphocytes presented with no antigen (Fig. 10). The results indicate the addition of promiscuous TCE's to the OspA fusion protein candidate enhance the proliferative lymphocyte responses of salmon vaccinated with the TCE-encoding vaccines against OspA (Fig. 10).

### 8. Protection of Immunized Salmonids Against *P. salmonis* Challenge

OspA fusion proteins were purified as inclusion bodies from *E. coli* BL21 and protein concentrations were determined using the BCA protein assay (Pierce). The relative percentages of the OspA fusion proteins within each preparation were determined by SDS-PAGE analysis and quantification of the fusion protein bands using a Gel Documentation system and AlphaEase software. Each protein sample was fixed by the addition of formalin (1 ml/L) and incubation with shaking at 15°C for 24 hr. Each protein solution was added aseptically to diluent (oil in water adjuvant) to obtain a final target protein concentration of 250 mg/L.

Coho salmon (~15 g) were anaesthetized (1 ppm metomidate hydrochloride), fin clipped for group identification, and intraperitoneally injected with 0.2 ml of vaccine with 60 fish per group. There were 6 groups in total: C17E2, CT17E2, CM17E2, CMT17E2, CM17E2 plus CT17E2 (1:1), and an adjuvant control. Salmon were held for 8 weeks in freshwater at 8.5°C post-vaccination.

All vaccinated coho were anaesthetized (1 ppm Marinil) and IP injected with 0.1 ml of *P. salmonis* infected CHSE-214 cell culture supernatant (~10<sup>6</sup> TCID<sub>50</sub>/ml). Salmon were maintained in freshwater at 13°C post-challenge and mortalities were logged. External and internal observations along with PCR of kidney and central liver sections using *P. salmonis* 16S rRNA primers (Giovannoni, 1991; Marshall, *et al.*, 1998) were performed for confirmation of mortality.

RPS is calculated to generate a numerical value representing the level of protection elicited by a vaccine. In general, RPS is calculated as a ratio of the cumulative mortality of a test group to the cumulative mortality of an unvaccinated group.  $RPS = [1 - (\% \text{ mortality of test group} \div \% \text{ mortality of control group})] \times 100\%$ .

Mortalities in the TCE OspA construct vaccinated groups began 7-10 days after the control group (Fig. 11). Cumulative mortality reached 85.5% in the control group (Fig. 11). The C17E2 vaccinated group reached 59.6% cumulative mortality, 30.2% RPS (Fig. 11). The CT17E2 vaccinated group reached a cumulative mortality of 35.6%, 58.4% RPS (Fig. 11). CM17E2 vaccinated salmon reached 20.0%, 76.6% RPS (Fig. 11). Salmon vaccinated with a 1:1 mixture of CM17E2 and CT17E2 reached 18.6% cumulative mortality giving a 78.2% RPS (Fig. 11). The lowest mortality was observed in the CMT17E2 vaccinated group, with only 14.5% cumulative mortality and an 83.0% RPS (Fig. 11).

The results indicate that adjuvant controls (o) had severe mortalities (>80%) and the CMT17E2 vaccinates (□) were significantly protected with only 14.5% mortality (Fig. 11).

While the present invention has been described in terms of the best mode of a preferred embodiment, it will be appreciated by one of ordinary skill that the spirit and scope of the invention is not limited to those embodiments, but extend to the various modifications and equivalents as defined in the appended claims.

## Claims

1. A method for the protection of a poikilothermic fish against infection by the bacterial pathogen *Piscirickettsia salmonis* comprised of administering either intraperitoneally, by immersion, or orally or by any combination of routes to said animal an immunogenic amount of a pharmaceutical composition comprising a principal antigen, the OspA lipoprotein, its variants, its non-lipidated form, or antigenic peptides derived or synthesized thereof, with or without an adjuvant.
2. A method as in claim 1 where the OspA antigen or a variants thereof are fused to at least one other protein or protein fragment either at the N or C terminus or both where that protein may be either used to facilitate expression and/or the formation of insoluble intracellular aggregates (inclusion bodies), soluble intracellular, extracellular, or periplasmic protein.
3. A method as in claim 1 where the OspA antigen or a variants thereof are fused to other proteins or protein fragments where those proteins or protein fragments are lymphocyte T and/or B cell epitopes.
4. A method as in claim 3 whereby all vaccine antigens against any bacterial, viral and/or parasitic diseases of fin fish has been fused to other proteins or protein fragments where those proteins or protein fragments are any lymphocyte T and/or B cell epitopes.
5. A method as in claim 3, where the said vaccine or variants thereof are encapsulated in or adsorbed to or are in the form of an insoluble polymeric matrix.
6. A method as in claim 5, where the principle OspA antigen, its variants, fragments, fusion proteins, or synthetic peptides thereof comprise sequence homologues of the OspA protein.
7. A method as in claim 6 where the vaccine antigen is formulated with or without an adjuvant.
8. A method as in claim 7 whereby any recombinant vaccine antigen, its variants or fusion protein constructs thereof are used as a vaccine, with or without other related or non-related vaccine immunogens or adjuvants singly or in combination, against any fin-fish disease caused by either a virus, bacteria or parasite.
9. A method as in claim 6 where the route of administration ~~is~~ of either a protein, lipoprotein or DNA vaccine version singly or in combination is administered either orally, intraperitoneally, intramuscularly, intradermally or by immersion or spraying or by any combination of these methods.

10. A method as in claim 6, where DNA of a sequence corresponding to that of *ospA*, fragments or synthetic oligonucleotides thereof or of DNA sequence homologues of *ospA*, fragments or synthetic oligonucleotides derived thereof are used as a vaccine.
11. A method as in claim 3, where the principle antigen is either that corresponding to OspA or a OspA homologue where the sequence has been optimized for expression in a suitable expression host microorganism such as an *E. coli* bacterial strain.
12. A method as in claim 3 where the expression of the OspA protein, its variants, lipoprotein version or antigenic peptides derived or synthesized thereof in *E. coli* is effected by a promoter.
13. An immunological method for the detection of humoral antibody to protein OspA or to *P. salmonis* in sera of poikilothermic fishes where either the OspA protein, a fragment or synthesized peptide thereof or OspA and its fusion partner are used to adsorb or bind to fish immunoglobulin from fish sera.
14. A method whereby any prokaryotic or eukaryotic expression systems are used to express the OspA protein, its variants, a fragment or synthesized peptide thereof, a fusion partner-OspA protein thereof or where OspA proteins or protein fragments are expressed with T and/or B cell epitopes.
15. An isolated nucleic acid fragment encoding a 17 kDa protein, wherein said protein is immunoreactive with anti- *P. salmonis* serum, and wherein said protein has an amino acid sequence of SEQ ID NO: 2 encompassing amino acid substitutions, additions and deletions that do not alter the function of said protein.
16. The nucleic acid fragment of claim 15, comprising a contiguous sequence of SEQ ID NOs:3 & 5 or the full length complement thereof.
17. The nucleic acid fragment of claim 15 operatively linked to a promoter.
18. The nucleic acid fragment of claim 17 wherein the promoter is a recombinant promoter.
19. A vaccine comprising a contiguous nucleic acid sequence of SEQ ID NOs: 1, 3 & 5.




20. A vector comprising a contiguous nucleic acid sequence of SEQ ID NOs: 1, 3 & 5.
21. The vector of claim 20, wherein the vector is an expression vector capable of expressing a peptide encoded by SEQ ID NOs:1, 3 & 5..
22. A host cell comprising the nucleic acid fragment of SEQ ID NOs:1, 3 & 5.
23. A method for producing a recombinant 17 kDa antigen of *P. salmonis* comprising the steps as outlined in Examples 4 & 5.
24. A method for determining previous sensitization of a subject with the OspA polypeptide of *P. salmonis* comprising the steps as outlined in Example 6.
25. Use of the OspA polypeptide or DNA encoding the gene for OspA as well as those DNA regions flanking that gene of *P. salmonis* in the manufacture of a diagnostic agent.
26. The method of incorporation of highly immunogenic promiscuous TCE's into one or more chimeric fusion proteins in fish.
27. The method as defined in claim 26, wherein the fish is a selected salmonid.
28. The method of incorporation of highly immunogenic promiscuous TCE's into OspA fusion protein to elicit immunostimulatory effects in the immune system of fish.
29. The method as defined in claim 28, wherein the fish is a selected salmonid.
30. The method as defined in claims 28, implemented by a vaccine.
31. A vaccine for eliciting immunostimulatory effects in the immune system of fish comprising selected highly immunogenic promiscuous TCE's incorporated into one or more chimeric fusion proteins.
32. A vaccine as defined in claim 31, wherein the chimeric fusion protein is OspA.

## Abstract of the Disclosure

**Vaccines and Agents for Inducing Immunity in Fish Against Rickettsial Diseases, And Associated Preventative Therapy**


The use of the 17 kDa outer surface lipoprotein (OspA) of *Piscirickettsia salmonis*, or its homologues, as the basis of, or part thereof, a recombinant vaccine for salmonid rickettsial septicaemia and other rickettsial diseases is disclosed. Surface antigens of the bacterial pathogen *P. salmonis* are characterized and an immunoreactive antigen, namely the 17 kDa outer surface lipoprotein OspA of *P. salmonis*, as well as the nucleic acid segment that encodes the OspA immunoreactive antigen, is identified and characterized. Diagnostic techniques including the use of hybridization probes and primers as well as the production of specific antigens and antibodies that may be used in immunization techniques for inducing immunity against *P. salmonis* and other rickettsial diseases are disclosed, as are the development of recombinant vaccines for SRS and other rickettsial diseases based on the 17 kDa lipoprotein OspA. Augmentation of protective immunity by the inclusion of promiscuous T lymphocyte epitopes (TCE's) in fusion protein constructs in salmonids and to the use of bacterial protein inclusion bodies as a source of the protective immunogen is also disclosed.

**FIGURE 1. WESTERN BLOT ANALYSIS OF *P. SALMONIS***



## FIGURE 2

### A. ORF's in the region of the *ospA* gene from *P. salmonis*



### B. DNA sequence of *ospA* gene from *P. salmonis* (SEQ ID:1)

ATGAACAGAGGATGTTTGCAGGTAGTAGTCTAATTATTATCAGTGTGTTTTAGTTGGCTGTGCCCAGA  
 ACTTTAGTTCGTCAAGAAGTCCGAGCTGCGACTGCGGCTGTTGTTGGCGGTGTTGCTGGCCAGCTGTTTGG  
 TAAAGGTAGTGGTCGAGTTGCAATGGCCATTGGTGGTGTCTGTTTTGGGTGGATTAAATTGGTTCTAAAATC  
 GGTCAATCGATGGATCAGCAGGATAAAATAAAGCTAAACCAGAGTTTGGAAAAGGTAAAAGCAGGGCAAG  
 TGACACGTTGGCGTAATCCAGATACAGGCAATAGTTATAGTCTTGAGCCAGTGGTACTTACCAGCGTTA  
 CAATAAGCAAGAGCGTCGCCAGCAATATTGTGAGAAATTCAGCAAAGCCGATGATTGCAGGGCAGAAG  
 CAAGAGATTACGGCACTGCATGCCGGCAACCGGATGGTCGTTGGCAAGTCATTTCACAGAAAAA

### Amino acid sequence of OspA protein (SEQ ID:2)


MNRGCLQGSSLIISVFLVGCANFSRQEVGAATGAVVGGVAGQLFGKSGSRVAMAIGGAVLGGLIGSKI  
 GQSMDDQDKIKLNQSLKVKAGQVTRWRNPDTGNSYSVEFPVRTYQRYNKOERRQOYCREFOOKAMLAGQK  
 QEIYGTACRQPDGRWQVISTEK

### C. Sequence alignment of the OspA proteins of *P. salmonis* and *R. prowazekii*


	10	20	30	40	
<i>P. salmonis</i> :	MNRGCLQGSSLIISV	FLVGCANFSRQEVGA	ATGAVVGGVAGQL	FGKSGSRVAMAIGG	
<i>R. prowazekii</i> :	MKLISKIMLAIAAS	MLAANGQSGMKNQ	CTGILLGAGCAHLC	SQ	
	10	20	30	40	
	50	60	70	80	90
<i>P. salmonis</i> :	EGKSGSRVAMAIGG	AVLGGLIGSKI	GQSMDDQDKIKLN	QSLKVKAGQVTR	WRNPDTGNSYSVE
<i>R. prowazekii</i> :	EGKSGSRVAMAIGG	AVLGGLIGSKI	GQSMDDQDKIKLN	QSLKVKAGQVTR	WRNPDTGNSYSVE
	50	60	70	80	90
	100	110	120	130	140
<i>P. salmonis</i> :	FPVRTYQRYNKOERR	QOYCREFOOKAM	LAGQKQEIYGTACR	QPDGRWQVISTEK	
<i>R. prowazekii</i> :	FPVRTYQRYNKOERR	QOYCREFOOKAM	LAGQKQEIYGTACR	QPDGRWQVISTEK	
	100	110	120	130	140
	150	160			
<i>P. salmonis</i> :	QEIYGTACRQPDGR	WQVISTEK			
<i>R. prowazekii</i> :	QEIYGTACRQPDGR	WQVISTEK			
	150	160			

**FIGURE 3**

**A. Map of plasmid pBC-17kDa encoding the *ospA* ORF.**




**B. Western blot analysis of OspA expression.**



**FIGURE 4.**

**A. Strategy for construction of the *E. coli* codon optimized *ospA* gene.**



**B. Oligonucleotide #1 (SEQ ID:9)**

CGCCAGGGTTTCCAGTCACGACGGATCCGTCTCATATGCGTGGTTGCCTGCAGGGCAGCTCTCTGATC  
ATTATCTCTGTTTTCTGGTGGGTTGCGCCAGAACTTCAG

**Oligonucleotide #2 (SEQ ID:10)**

TGGGTTGCGCCAGAACTTCAGCCGCGCAGGAAGTTGGCGCGGCCACCGGTGCGGTTGTGGGCGGTGTTGC  
CGCCAGCTGTTCGGTAAAGGCTCTGGTCTGTGTGGCGATG

**Oligonucleotide #3 (SEQ ID:11)**

AAAGGCTCTGGTCTGTGTGGCGATGGCCATCGGCGGTGCGGTTCTGGGCGGTCTGATTGGCTCTAAAATCG  
GTCAGAGCATGGACCAAGCAGGATA

**Oligonucleotide #4 (SEQ ID:12)**

GTTCCACAGAGTAGCTGTTACCGGTGTCCGGATTACGCCAACGAGTAACCTGGCCGGCTTTCAGTTTTTC  
CAGAGACTGGTTCAGTTTGATTTTATCCTGCTGGTCCATGCTCTGACC

**Oligonucleotide #5 (SEQ ID:13)**

GGTGCCGTAGATTTCTGTTTTCTGACCTGCGATCATGGCTTTCTGCTGAAATTCGCGGCAGTACTGCTGA  
CGGCGTTCTCTGTTTGTGTGTAACGCTGGTAGGT

**Oligonucleotide #6 (SEQ ID:14)**

CGTCTCTCTGTCCTGGTCCGAATTGAGATAAGCTTATTTTTCGGTGCTAATCACCTGCCAGCGGCCATCC  
GGCTGACGGCACGCGGTGCCGTAGATTTCTGTTTTCTGAC

**C. DNA sequence of *E. coli* optimized *ospA* gene, 17e2 (SEQ ID:3)**

ATGCGTGGTTGCCTGCAGGGCAGCTCTCTGATCATTATCTCTGTTTTCTGGTGGGTTGCGCCAGAACT  
TCAGCCGCCAGGAAGTTGGCGCGGCCACCGGTGCGGTTGTGGGCGGTGTTGCGGCCAGCTGTTCCGTAA  
AGGCTCTGGTCTGTGTGTCGATGGCCATCGGCGGTGCGGTTCTGGGCGGTCTGATTGGCTCTAAAATCGGT  
CAGAGCATGGACCAAGCAGGATAAAAATCAAACTGAACCACTCTCTGGAAGTGAAGCCGGCCAGGTTA  
CTCGTTGGCGTAATCCGACACCGGTAACAGCTACTCTGTGGAACCGGTTCCGACCTACCAGCGTTACAA  
CAACAGGAACGCGTCAGCAGTACTGCCGCGAATTTGAGCAGAAAGCCATGATCGCAGGTGAGAAACAG  
GAAATCTACGGCACCGGTGCCCTCAGCCGGATGGCCGCTGGCAGGTGATTAGCACCGAAAAA

## FIGURE 5

### A. Amino acid sequence of optimized OspA protein, 17E2, (SEQ ID:4).

MRGCLQGSSLIISVFLVGCQNFSRQEVGAATGAVVGGVAGQLFGKGSGRVSMAGGAVLGGLIGSKIG  
QSMDOQDKIKLNQSLKVKAGQVTRWRNPDTGNSYSVEFVRTYQRYNKQERRQOYCREFOQKAMIAGQKQ  
EIYGTACPQPDGRWQVISTEK

### B. DNA sequence of c17e2 *ospA* construct with N-terminal fusion partner (SEQ ID:5).


ATGTCAGTTGAATTCTACAACTCTAACAAATCAGCACAAACAACTCAATTACACCAATAATCAAATTA  
CTAACACATCTGACAGTGAATTTAAATTTAAATGACGTAAAAGTTAGATAATTATTACACAAGTGATGGTAC  
ACAAGGACAAACTTTCTGGTGTGACCATGCTGGTGCAATTATTAGGAAATAGCTATGTTGATAACACTAGC  
AAAGTGACAGCAAACTTCGTTAAAGAAAACAGCAAGCCCAACATCAACCTATGATACATATCTGGATCCGT  
CTCATATGCGTGGTTGCCTGCAGGGCAGCTCTCTGATCATTAATCTCTGTTTTCTGGTGGGTTCGCCCCA  
GAACTTCAGCCGCCAGGAAGTTGGCGCGGCCACCGGTGCGGTTGTGGGCGGTGTTGCCGCCAGCTGTTTC  
GGTAAAGGCTCTGGTCTGTGTGATGGCCATCGGCGGTGCGGTTCTGGGCGGTCTGATTGGCTCTAAAA  
TCGGTCAGAGCATGGACCAGCAGGATAAAATCAAACCTGAACAGTCTCTGGAAAAAGTGAAAGCCGGCCA  
GGTTACTCGTTGGCGTAATCCGGACACCGGTAACAGCTACTCTGTGGAACCGGTTGCGACCTACCAGCGT  
TACAACAAACAGGAACGCCGTGAGCAGTACTGCCGCGAATTTGAGCAGAAAGCCATGATCGCAGGTGAGA  
AACAGGAAATCTACGGCACCGCGTGCCCTCAGCCGGAATGGCCGCTGGCAGGTGATTAGCACCGAAAA

### C. Amino acid sequence of C17E2 OspA construct with N-terminal fusion partner (SEQ ID:6).


MSVEFYNSNKSQNTSITPIIKITNTSDSDLNLNDVKVRYYYTSDGTQGQTFWCDHAGALLGNSYVDNTS  
KVTANFVKETASPTSTYDTYLDPSHMRGCLQGSSLIISVFLVGCQNFSRQEVGAATGAVVGGVAGQLF  
GKGSGRVSMAGGAVLGGLIGSKIGQSMDOQDKIKLNQSLKVKAGQVTRWRNPDTGNSYSVEFVRTYQRYNKQERRQOYCREFOQKAMIAGQKQEIYGTACPQPDGRWQVISTEK

**FIGURE 6**

**A. Expression vectors encoding the optimized *ospA* fusion constructs**




**B. SDS-PAGE analysis of C17E2 expression.**






## FIGURE 7

Map of the *ospA*-fusion construct encoding a C-terminal fusion partner under T7 promoter control.



## FIGURE 8

### A. CLONING STRATEGY FOR OSPA TCE FUSION PROTEIN CONSTRUCTS.



### B. (a) Nucleotide sequence of the tt P2 oligonucleotide (SEQ ID:17)

CGCCAGGGTTTTCCAGTCACGACGGATCCGTCTCATATGCAGTACATTAAAGCAAACCTCTAAATTCATC  
GGTATTACCGAACTGATTAATTAAGCTTCGGACCAGGACGAGAGGACG

### (b) Nucleotide sequence of the MVF oligonucleotide (SEQ ID:18)

CGCCAGGGTTTTCCAGTCACGACGGATCCGTCTCATATGCTGTCTGAAATCAAAGGTGTTATCGTTCAT  
CGTCTGGAAGGCCTGATTAATTAAGCTTCGGACCAGGACGAGAGGACG

### (c) Amino acid sequence of the tt P2 TCE (SEQ ID:19)


QYIKANSKFIGITEL

### (d) Amino acid sequence of the MVF TCE (SEQ ID:20)

LSEIKGVTVHRLEGV


## FIGURE 9

Coho salmon antibody titres against OspA-fusion protein candidate vaccines.




**FIGURE 10**

**Whole lymphocyte proliferative response to OspA-fusion proteins in Atlantic salmon.**



**FIGURE 11**

**Vaccine trial in coho salmon of OspA fusion proteins.**



COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled VACCINES AND AGENTS FOR INDUCING IMMUNITY IN FISH AGAINST RICKETTSIAL DISEASES, AND ASSOCIATED PREVENTATIVE THERAPY, the specification of which

- ☒ is attached hereto.  
☐ was filed on \_\_\_\_\_ as Application No. \_\_\_\_\_.  
☐ was described and claimed in PCT International Application No. \_\_\_\_\_, filed on \_\_\_\_\_, and as amended under PCT Article 19 on \_\_\_\_\_ (if applicable).  
☐ and was amended on \_\_\_\_\_ (if applicable).  
☐ with amendments through \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. If this is a continuation-in-part application filed under the conditions specified in 35 U.S.C. § 120 which discloses and claims subject matter in addition to that disclosed in the prior copending application, I further acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	Yes	No	[ ] [ ]
-------------------	--------------------	---------------------------------	-----	----	---------

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

**60/154,437**

(Application No.)

**September 17, 1999**

(Filing Date)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States,

listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

(Application No.) \_\_\_\_\_ (Filing Date) \_\_\_\_\_ (Status: patented, pending, abandoned)

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from \_\_\_\_\_ as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application, to file a corresponding international application, and to transact all business in the Patent and Trademark Office connected therewith:

<u>Name</u>	<u>Reg. No.</u>
Douglas D. Hancock	35,889
Patrick W. Hughey	31,169
Mark M. Meininger	32,428
John Dawson	39,504

Address all telephone calls to Douglas D. Hancock at telephone number (503) 249-7066.

Address all correspondence to:

ipsolon llp  
4370 NE Halsey Street  
Portland, OR 97213

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor: Michael A. Kuzyk

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Victoria, British Columbia, Canada

Citizenship: Canada

Post Office Address: #303 1535 Jubilee Ave, Victoria, B.C. V8R 4N4, Canada

Full name of second joint inventor: Jan Burian

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Victoria, British Columbia, Canada

Citizenship: Canada

Post Office Address: #80 1732 Newton Street, Victoria, B.C. V8R 2R2 Canada

Full name of third joint inventor: William W. Kay

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Victoria, British Columbia, Canada

Citizenship: Canada

Post Office Address: 3620 Cadboro Bay Road, Victoria, B.C., V8R 5K8 Canada

Full name of fourth joint inventor: Julian C. Thornton

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Victoria, British Columbia, Canada

Citizenship: Canada

Post Office Address: 1219 Oscar Street, Victoria, B.C., V8R 2X6